Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.
Using atomic absorbance spectrometry with Zeeman background correction, we measured platinum-DNA adduct levels in leukocyte DNA of 49 patients receiving therapy consisting of only carboplatin and cisplatin. Twenty-four histological types of malignancy were included in the cohort. Peripheral blood leukocytes were collected at defined times during the first two cycles of treatment. The relationship between adduct level and disease response was highly statistically significant during cycle 1 of therapy (two-sided P = 0.007 at day 2), but statistical significance was lost during cycle 2. On all days studied, median and mean adduct levels were consistently higher in responders as compared to nonresponders (summary two-sided P = 0.0004). These data suggest that the processes which protect cellular DNA may be common to malignant and nonmalignant rapidly dividing tissues of the same individual, regardless of the type of tumor that individual may harbor.
Reed
E
E
Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892.
Parker
R J
RJ
Gill
I
I
Bicher
A
A
Dabholkar
M
M
Vionnet
J A
JA
Bostick-Bruton
F
F
Tarone
R
R
Muggia
F M
FM
D016190:Carboplatin / Q000378:metabolism* / Q000627:therapeutic use; D002945:Cisplatin / Q000032:analysis / Q000097:blood*; D004247:DNA / Q000032:analysis / Q000097:blood*; D018736:DNA Adducts; D006801:Humans; D007962:Leukocytes / Q000737:chemistry / Q000378:metabolism*; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy; D011446:Prospective Studies; D013054:Spectrophotometry, Atomic
D018736:DNA Adducts; C057270:cisplatin-DNA adduct; D004247:DNA; D016190:Carboplatin; D002945:Cisplatin